Pharma BD Deal Intelligence
A durable #2-in-cataract-surgery bolt-on that never became the category leader Alcon remains — solid, not spectacular
Full analysis, sources & comparables →The all-cash $4.325B transaction added cataract surgery, laser refractive surgery, and consumer eye health to J&J's contact-lens business, reshaping the…
Closure created Johnson & Johnson Vision, with J&J's Ashley McEvoy stating the combined unit was 'poised to become a world leader in eye health' across…
Industry coverage framed the deal as a strategic vault into surgical ophthalmology, leveraging demographic tailwinds from an aging population requiring…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Abbott agreed to sell Abbott Medical Optics to Johnson & Johnson for $4.325B all-cash. AMO's portfolio: cataract surgery, laser refractive surgery, and consumer eye health products with $1.1B annual sales. Combined with J&J's ACUVUE Brand Contact Lenses to form Johnson & Johnson Vision. Closed February 2017.
A durable #2-in-cataract-surgery bolt-on that never became the category leader Alcon remains — solid, not spectacular
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) (this deal) | 2016 | $4.3B | 66 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2016 deals · Johnson & Johnson deals · Ophthalmology deals